Speciality Medicines Ltd

Speciality Medicines Annual Report

Speciality Medicines Limited has submitted its Annual Report for the financial year 2025-26 to the exchange, complying with regulatory filing requirements.

Speciality Medicines Annual General Meeting

Speciality Medicines Limited scheduled its 5th Annual General Meeting for September 28, 2026. The board also approved the draft Directors' Report for FY 2025-26.

Speciality Medicines Regulatory Approval

Speciality Medicines Limited received regulatory approval in Ethiopia for two additional pharmaceutical formulations, Olanzapine and Diazepam tablets. The company now has 12 registered products in Ethiopia.

Speciality Medicines Business Update

Speciality Medicines Limited received regulatory approval for two new products, Olanzapine and Diazepam tablets, in the Ethiopian market, strengthening its international export portfolio.

Speciality Medicines Other Announcement

Speciality Medicines Limited has appointed Capital Bridge Advisory Service Private Limited as its Investor and Public Relations agency to enhance its investor relations and communication efforts.

Speciality Medicines H2 FY26 Results: Net Profit ₹8.2 Cr, Up 203.7% YoY

Speciality Medicines Ltd reported revenue from operations of ₹44.8 Cr (+45.5% YoY) and net profit of ₹8.2 Cr (+203.7% YoY) for H2 FY26.

Key figure

Net profit ₹8.2 Cr · +203.7% YoY

Speciality Medicines Financial Results

Speciality Medicines Ltd reported its audited standalone financial results for the year ended March 31, 2026. The company also confirmed full utilization of its IPO proceeds.

Speciality Medicines Board Meeting Date

Speciality Medicines Ltd scheduled a board meeting for May 28, 2026, to approve audited financial results. The trading window remains closed for insiders until May 30.

Speciality Medicines Other Announcement

Speciality Medicines Ltd submitted contact details of Key Managerial Personnel authorised under SEBI Regulation 30(5). The authorised KMPs include the Chairman & Managing Director, Whole-time Director, and Company Secretary. This administrative update ensures compliance with materiality disclosure requirements.

Speciality Medicines Bags ₹18.6 Cr Order

Speciality Medicines Limited secured a distribution and sales order from an international entity worth USD 2 million (₹18.6 Crore). The arrangement focuses on pharmaceutical finished products and is expected to significantly enhance the company's distribution network and revenue visibility.

Value

₹18.60 Cr

Speciality Medicines Bags ₹13.95 Cr Order

Speciality Medicines Limited secured a distribution contract worth USD 1.5 million (approx. ₹14 Crore) from an international pharmaceutical entity. The arrangement aims to enhance the company's global distribution network and revenue visibility. No promoters or group companies have interests in the transaction.

Value

₹13.95 Cr

Speciality Medicines Price Movement Clarification

Speciality Medicines Limited clarified to BSE that the recent significant movement in its share price is purely market-driven. The company confirmed it has consistently complied with SEBI LODR Regulations and has no undisclosed material information or developments that could impact price or operations.